Our industry leading antibody discovery and development capabilities have been recognized and validated through various strategic collaborations with leading biopharmaceutical companies in China. We expect these collaborations to generate substantial synergy with our in-house development and help us maximize the clinical and commercial value of our pipeline products.
We entered into a collaboration agreement with Kyinno Bio to co-develop a novel GPRC5D/BCMA/CD3 T-cell engager, MBS314.
We grant Climb Bio(NASDAQ stock code：CLYM）the exclusive rights to develop, manufacture and commercialize MIL116, an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China.
